Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study

References

• Safari H, Arab M, Rashidian A, Kebriaee-Zadeh A, Gorji HA. A comparative study on different pharmaceutical industries and proposing a model for the context of Iran. Iran J Pharm Res. 2018;17(4):1593.30568715
   PubMed Web of Science ®Google Scholar
• Rezapoor A, Azar FEF, Safari H, Arabloo J. Cost analysis of services delivered to patients with end-stage renal disease referring to bou-ali-sina hospital affiliated to Qazvin University of Medical Sciences. World Appl Sci J. 2012;18(6):796–802.
   Google Scholar
• Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries. DARU J Pharm Sci. 2013;21(1):52. doi:10.1186/2008-2231-21-52
   Web of Science ®Google Scholar
• Safari H, Ebrahimi E. Using modified similarity multiple criteria decision making technique to rank countries in terms of human development index. J Ind Eng Manage. 2014;7(1):254–275.
   Google Scholar
• Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. DARU J Pharm Sci. 2013;21(1):64. doi:10.1186/2008-2231-21-64
   Web of Science ®Google Scholar
• Salamzadeh J. Clinical pharmacy in Iran: where do we stand? Iran J Pharm Res. 2010;1–2.24363699
   PubMed Web of Science ®Google Scholar
• Cheraghali AM. Trends in Iran pharmaceutical market. Iran J Pharm Res. 2017;16(1):1.
   PubMedGoogle Scholar
• Varmaghani M, Hashemi-Meshkini A, Abdollahiasl A, et al. An overview to pharmaceutical financing in Iran. J Pharmacoecon Pharm Manage. 2016;2(1/2):45–49.
   Google Scholar
• Lu Y, Hernandez P, Abegunde D, Edejer T. The World Medicines Situation 2011. Geneva: Medicine expenditures World Health Organization; 2011.
   Google Scholar
• Abraham J, Bardelay D, Kleinke J, Bennion E, Kopp C. Education and debateMaking regulation responsive to commercial interests: streamlining drug industry watchdogsCommentary: concern over drug industry’s influence on regulatory policy in EuropeCommentary: much ado about a good thing Commentary: the freedom of informed choice. BMJ. 2002;325(7373):1164–1169. doi:10.1136/bmj.325.7373.116412433771
   PubMed Web of Science ®Google Scholar
• Fardazar FE, Safari H, Habibi F, Haghighi FA, Rezapour A. Hospitals’ readiness to implement clinical governance. Int J Health Policy Manage. 2015;4(2):69. doi:10.15171/ijhpm.2014.111
   Google Scholar
• Akhavan P, Mehralian G, Rasekh HR, Sadeh MR. The impact of intellectual capital efficiency on market value: an empirical study from Iranian pharmaceutical companies. Iran J Pharm Res. 2012;11(1):195–207.
   Web of Science ®Google Scholar
• Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage. 2005;20(4):291–306. doi:10.1002/(ISSN)1099-175116335079
   PubMed Web of Science ®Google Scholar
• Rasekh HR, Mehralian G, Vatankhah-Mohammadabadi AA. Situation analysis of R & D activities: an empirical study in Iranian pharmaceutical companies. Iran J Pharm Res. 2012;11(4):1013.24250532
   PubMed Web of Science ®Google Scholar
• Mehralian G, Gatari AR, Morakabati M, Vatanpour H. Developing a suitable model for supplier selection based on supply chain risks: an empirical study from Iranian pharmaceutical companies. Iran J Pharm Res. 2012;11(1):209.24250442
   PubMed Web of Science ®Google Scholar
• Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–1907. doi:10.1007/s11135-017-0574-829937585
   PubMed Web of Science ®Google Scholar
• Graneheim UH, Lundman B. Qualitative content analysis in nursing research: concepts, procedures and measures to achieve trustworthiness. Nurse Educ Today. 2004;24(2):105–112. doi:10.1016/j.nedt.2003.10.00114769454
   PubMed Web of Science ®Google Scholar
• Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive study. Nurs Health Sci. 2013;15(3):398–405. doi:10.1111/nhs.2013.15.issue-323480423
   PubMed Web of Science ®Google Scholar
• Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi:10.1093/intqhc/mzm04217872937
   PubMed Web of Science ®Google Scholar
• Ghaffari-Nasab N, Ahari S, Makui A. A portfolio selection using fuzzy analytic hierarchy process: a case study of Iranian pharmaceutical industry. Int J Ind Eng Comput. 2011;2(2):225–236. doi:10.5267/j.ijiec.2010.03.001
   Google Scholar
• Ni J, Zhao J, Ung COL, Hu Y, Hu H, Wang Y. Obstacles and opportunities in Chinese pharmaceutical innovation. Global Health. 2017;13(1):21. doi:10.1186/s12992-017-0244-628340579
   PubMed Web of Science ®Google Scholar
• Mehta A, Farooqui HH, Selvaraj S. A critical analysis of concentration and competition in the Indian pharmaceutical market. PLoS One. 2016;11(2):e0148951. doi:10.1371/journal.pone.014895126895269
   PubMed Web of Science ®Google Scholar
• Guennif S, Ramani S. Catching up in Pharmaceuticals: A Comparative Study of India and Brazil. Maastricht University 2010.
   Google Scholar
• Mehralian G, Rasekh HR, Akhavan P, Ghatari AR. Prioritization of intellectual capital indicators in knowledge-based industries: evidence from pharmaceutical industry. Int J Inf Manage. 2013;33(1):209–216. doi:10.1016/j.ijinfomgt.2012.10.002
   Web of Science ®Google Scholar
• Varmaghani M, Meshkini AH, Farzadfar F, et al. Evaluation of productivity in Iranian pharmaceutical companies: a DEA-based Malmquist approach and panel data analysis. J Res Pharm Pract. 2015;4(2):51. doi:10.4103/2279-042X.15575025984541
   PubMedGoogle Scholar
• Cross HE, Sayedi O, Irani L, Archer LC, Sears K, Sharma S. Government stewardship of the for-profit private health sector in Afghanistan. Health Policy Plan. 2016;32(3):48–338.
   Web of Science ®Google Scholar
• Giesecke S. The contrasting roles of government in the development of biotechnology industry in the US and Germany. Res Policy. 2000;29(2):205–223. doi:10.1016/S0048-7333(99)00061-X
   Web of Science ®Google Scholar
• Mehralian G, Zarenezhad F, Rajabzadeh Ghatari A. Developing a model for an agile supply chain in pharmaceutical industry. Int J Pharm Healthcare Marketing. 2015;9(1):74–91. doi:10.1108/IJPHM-09-2013-0050
   Google Scholar
• Ding J, Xue Y, Liang H, Shao R, Chen Y. From imitation to innovation: A study of China’s drug R&D and relevant national policies. J Technol Manage Innovation. 2011;6(2):1–13. doi:10.4067/S0718-27242011000200001
   Google Scholar
• Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;(2). doi:10.1002/14651858.MR000033.pub3.
   Web of Science ®Google Scholar
• Mehralian G, Rajabzadeh A, Reza Sadeh M, Reza Rasekh H. Intellectual capital and corporate performance in Iranian pharmaceutical industry. J Intellectual Capital. 2012;13(1):138–158. doi:10.1108/14691931211196259
   Google Scholar
• Rahimi M, Ahmadi P, Khodadad HS. Commercial Effects of Iran’s Membership in the Wto in Drug Industry. Hakim Res J. 2011;14(2):73–77.
   Google Scholar